Engineering Stability
Tesamorelin solves Sermorelin's main limitation: rapid enzymatic degradation. The trans-3-hexenoic acid modification at the N-terminus blocks DPP-IV from cleaving the peptide, extending its active duration from minutes to hours.1
This modification is elegant in its simplicity — a single chemical group added to one end of the molecule transforms a short-acting research tool into a longer-acting compound suitable for less frequent administration in experimental protocols.
The Clinical Evidence Advantage
Tesamorelin (Egrifta) holds current FDA approval for HIV-associated lipodystrophy — giving it the most recent clinical evidence base of any compound in the OSYRIS Growth Hormone category. The clinical trial program provided data on:
Visceral fat reduction. Tesamorelin significantly reduced visceral adipose tissue (VAT) in clinical trials, as measured by CT scan. The effect was specific to visceral fat — subcutaneous fat was not significantly affected, and lean mass was preserved.2
Hepatic fat. Studies by Stanley et al. demonstrated that Tesamorelin reduced liver fat content in subjects with hepatic steatosis. This connects GH-axis biology to liver metabolism — a research area where Tesamorelin has uniquely strong clinical data.3
Safety profile. The clinical program confirmed no increase in diabetes incidence, no clinically meaningful changes in glucose metabolism, and manageable side effects (injection site reactions, edema) in the studied population.
Comparative GHRH Research
| GHRH Analog | Modification | DPP-IV Resistant | Duration | Clinical Data |
|---|---|---|---|---|
| Sermorelin (GRF 1-29) | None (minimum fragment) | No | ~10-20 min | Former FDA (diagnostic) |
| Tesamorelin | Hexenoic acid at N-terminus | Yes | Hours | Current FDA (lipodystrophy) |
| CJC-1295 (no DAC) | Multiple substitutions | Partially | 30+ min | Phase 2 |
Tesamorelin is the gold standard for sustained GHRH-R stimulation in clinical contexts. Sermorelin is the reference for unmodified pulsatile research. CJC-1295 offers intermediate stability.
Limitations
Tesamorelin's clinical data is specifically from HIV-associated lipodystrophy populations. Whether results generalize to non-HIV metabolic contexts is extrapolated but not proven. The FDA approval is indication-specific, not a general endorsement of GH-axis modulation.
Explore the Related Compounds
Jump from the journal into the matching catalog pages to inspect specs, pricing, citations, and the batch-specific COA.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) composed of 44 amino acids. It is studied for its role in stimulating endogenous growth hormone (GH) release via pituitary GHRH receptors. Tesamorelin is used exclusively for controlled scientific research and is not approved for therapeutic or diagnostic use.
Sermorelin
Sermorelin acetate (10mg) is a synthetic analog of growth hormone–releasing hormone (GHRH), consisting of the first 29 amino acids of the natural peptide. With ≥99% purity, this research peptide is used in laboratory studies exploring neuroendocrine regulation, aging models, and pituitary function. Supplied for research purposes only.
CJC NO DAC/Ipamorelin Blend
This blend combines CJC-1295 (No DAC) and Ipamorelin—two research peptides that act synergistically on the growth hormone (GH) axis. CJC-1295 stimulates GH-releasing hormone (GHRH) receptors, while Ipamorelin targets ghrelin receptors. Their combined use supports investigation into pulsatile GH secretion and downstream effects in cellular and endocrine research models.
Source Literature
Teichman SL, et al. "Prolonged GH and IGF-I stimulation by CJC-1295." JCEM, 2006. PubMed: PMID 16352683
Falutz J, et al. "Growth hormone-releasing factor in patients with HIV." NEJM, 2007. PubMed: PMID 18003859
Stanley TL, et al. "Tesamorelin effects on non-alcoholic fatty liver disease." Gut, 2014. PubMed: PMID 23929694
Frequently Asked Questions
Questions About Tesamorelin
Tesamorelin has an N-terminal modification that protects it from DPP-IV degradation, giving it a much longer active duration than unmodified Sermorelin.
Because it extends the peptide’s functional exposure in vivo, allowing more sustained GHRH receptor stimulation and a different GH-release profile.
It has been evaluated in regulated clinical programs, including FDA-approved use in HIV-associated lipodystrophy, which generated real imaging and safety data.
Clinical studies showed reductions in liver fat in certain populations, making Tesamorelin relevant not only to GH signaling but also to metabolic-liver research.
No. It remains an upstream pituitary stimulus, while compounds like IGF1-LR3 act downstream at the effector level.
Because its core mechanism is still GHRH receptor stimulation and endogenous GH release, even though the strongest clinical data focuses on body-composition endpoints.
Keep Following the Research Trail
Tesamorelin vs Sermorelin — Modified vs Unmodified GHRH
Tesamorelin vs Sermorelin compared: stabilized versus unmodified GHRH signaling, DPP-IV resistance, pulse duration, and clinical context.
Growth Hormone Peptides — The Somatotropic Axis Research Toolkit
Complete guide to GH axis research. GHRH analogs, GHRPs, IGF-1, GH fragments. Selectivity, synergy, pulsatile release. Every node mapped.
IGF1-LR3 — The Downstream Effector With Enhanced Bioavailability
IGF1-LR3 research overview covering reduced IGFBP binding, cell-culture use, IGF-1 receptor signaling, and downstream GH-axis biology.